The novel antimicrotubular taxane called cabazitaxel was developed to avoid the primary mechanism of resistance for docetaxel. the first-line treatment for patients with hormone-resistant prostate cancer (HRPC). However. its ability to increase the survival rate for HRPC is limited to a few months. https://www.havifrost.com/product-category/bedside-cases/